Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

cquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 2015 The Thomas Brain Health ... a groundbreaking pilot study to see if early ... as little as three to six months. , ... nutritional medicine—will aggressively target and simultaneously treat the ... aging brain. These include oxidative stress, neuroinflammation, mitochondrial ...
(Date:4/23/2015)... April 23, 2015 BioTE Medical President and ... "Age Healthier Live Happier - Avoiding Over-Medication through Natural ... Management Medicine Group Conference at JW Marriott / Ritz ... ",Age Healthier Live Happier, is a welcomed response ... and searching for a higher quality of life thanks ...
(Date:4/23/2015)... SAN DIEGO , April 23, 2015  Neurocrine ... the Company will report its first quarter 2015 results ... 2015. Neurocrine will then host a live conference call and ... Company update Thursday morning, April 30, 2015 at 8:00 ... Participants can access the live conference call by dialing ...
(Date:4/23/2015)... Jose, California (PRWEB) April 23, 2015 ... Predictive diagnostics refer to a series of genetic ... as cystic fibrosis, Lou Gehrig's disease, Huntington's disease, ... in examining the gene composition and interaction in ... the disease as well as the response to ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3
... Firmenich,s world leadership in the ... flavor ingredients, - New S2383 flavor enhancer may be used in ... healthcare products to reduce the need for sucralose, ... Inc. (Nasdaq: SNMX ), a leading company,focused on using proprietary ...
... BOSTON, Nov. 6 Solos Endoscopy, Inc. (Pink,Sheets: SNDY) ... a,significant purchase order for laparoscopic instruments from the St. ... client of Solos,Endoscopy,s for over 19 yrs and it ... Saint Mary,s Hospital has played a vital role in ...
... Inc. (NTI(R)) (Nasdaq: NTII ) today announced its ... first quarter of the,company,s fiscal year ending June 30, ... was $3.6 million, compared to $3.9 million for the,three ... million,for the first quarter of fiscal 2009 compared to ...
Cached Biology Technology:SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 3Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 4Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 5
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2
... After a year of studying up close the symbiotic relationship ... University biologist has advanced the scientific understanding of biological diversity. ... relationship between two or more organisms that can be parasitic ... diversity as predation and competition. The Proceedings ...
... , Feb. 5, 2013 Reportlinker.com ... is available in its catalogue: ... and Prognostic Biomarkers, 2013 ... Endothelial Growth Factor (VEGF), which plays an ...
... When it comes to gene sequencing and personalized medicine for ... proteins are relatively easy to target with drugs and plenty ... study, University of Michigan Comprehensive Cancer Center researchers assess the ... kinases are acting up in a particular tumor. They go ...
Cached Biology News:Pirate-like flies connect symbiosis to diversity 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 3VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 4VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 5Study finds potential to match tumors with known cancer drugs 2Study finds potential to match tumors with known cancer drugs 3
...
... custom microplate coating using advanced automated high throughput microplate processing ... We can also accommodate virtually any lot size of the ... , 8 and 12 well ... 384 well microplate, ...
... first biological reagent that eliminates ... not just by inhibiting growth. ... agent that can be used ... The cytotoxicity of Mynox is ...
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
Biology Products: